Healthcare
Vericel Corporation(VCEL)
Live Price
Offline$37.46
-2.88% today
1Y Change
-11.04%
Window
Jun 20, 2025 โ Jun 10, 2026
- Market Cap
- $1.81B
- Revenue Growth
- +16.5%
- EPS Growth
- +57.1%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 20, 2025 โ Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vericel Corporation (VCEL) is a Healthcare stock with a market cap of $1.81B and listed on NASDAQ. The stock last traded around $37.46 and down 11.0% across the available one-year price window (Jun 20, 2025 โ Jun 10, 2026). Baseline metrics include revenue growth of +16.5%, EPS growth of +57.1%, a dividend yield of 0.0%. What stands out right now is revenue +16.5%, EPS +57.1%, free cash flow +525.9% with operating margin 4.0% and ROIC 2.3%. Valuation already assumes a fairly strong business story at P/E 108.9 and price/sales 6.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VCEL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.5% vs +7.6% peer median
Operating Margin
Below sector median
+4.0% vs +19.4% peer median
P/E
Above sector median
108.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 7, 2026 with an EPS surprise of +20.0% and a revenue surprise of +7.5%.
The operating story is still moving forward
Revenue is running at +16.5% and EPS at +57.1%, with operating margin around 4.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 30, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +20.0% | -4.8% | -5.7% | +3.3% |
2026 Feb 26, 2026 | +0.0% | -5.3% | -9.8% | -18.2% |
2025 Nov 6, 2025 | +600.0% | +0.5% | +2.8% | -6.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VCEL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VCEL Max Drawdown
-32.30%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VCEL and SPY.
Company Overview
Vericel Corporation
NASDAQ Capital Market
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Dominick C. Colangelo
- IPO Date
- Feb 4, 1997
- Employees
- 357
- Street Address
- 64 Sidney Street
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 588 5555
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 108.9
- EV/EBITDA
- 60.9
- Price/Sales
- 6.6
- Price/Book
- 5.1
Growth
- Revenue
- +16.5%
- EPS
- +57.1%
- Free Cash Flow
- +525.9%
Profitability
- Gross Margin
- 74.4%
- Operating Margin
- 4.0%
- Net Margin
- 6.0%
- ROE
- 5.2%
- ROIC
- 2.3%
Balance Sheet
- Debt/Equity
- 0.28
- Current Ratio
- 5.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.